Straits Times Index
3,435.53 +20.02 (+0.59%) Nikkei
40,913.65 +332.89 (+0.82%) Hang Seng
18,027.91 +49.34 (+0.27%) FTSE 100
8,216.54 +45.42 (+0.56%) Bitcoin USD
58,162.60 -2,635.95 (-4.34%) CMC Crypto 200
1,224.59 -36.60 (-2.90%)
CDNA Feb 2025 10.000 put
| Previous close | 1.5800 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 3.6000 |
| Strike | 10.00 |
| Expiry date | 2025-02-21 |
| Day's range | 1.5800 - 1.5800 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Business WireLandmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
BRISBANE, Calif., June 03, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicine1 of findings from the largest, real-world study of its kind, assessing the role of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and of
Business WireAI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
BRISBANE, Calif., May 30, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia.
Business WireCareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
BRISBANE, Calif., May 29, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.’s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent).
